ADMA Biologics, Inc. (NASDAQ: ADMA) entered into an agreement with KPMG LLP on October 31, 2024, detailing KPMG’s role as the company’s new independent registered public accounting firm. The effective date of this engagement will coincide with the filing of ADMA Biologics’ Quarterly Report on Form 10-Q for the fiscal quarter ending September 30, 2024. KPMG’s responsibilities will encompass conducting an audit of the company’s consolidated financial statements for the fiscal year ending December 31, 2024. These audited financial statements are anticipated to be included in ADMA Biologics’ Annual Report on Form 10-K, expected to be filed on or before March 3, 2025.
During the fiscal years ending December 31, 2023, and 2022, as well as the interim period up to October 31, 2024, ADMA Biologics did not engage in consultations with KPMG regarding specific transactions’ accounting principles or potential audit opinions. Additionally, there were no disagreements or reportable events as defined under Regulation S-K during this period.
Please note that this article summarizes the content of an 8-K SEC Filing by ADMA Biologics, Inc. For detailed information, readers are encouraged to refer directly to the official document.
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read ADMA Biologics’s 8K filing here.
ADMA Biologics Company Profile
ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.
See Also
- Five stocks we like better than ADMA Biologics
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Microsoft Can Hit New All-Time Highs This Year – Here’s Why
- Compound Interest and Why It Matters When Investing
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
